BenzingaSeptember 10, 2026 at 5:02 AM NYLast Month
Jaguar Health Announces All Pediatric Participants In Napo Pharmaceuticals' Crosover Clinical Study Have Entered Extension Phase To Get Doses Of Crofelemer To Treat Microvillus Inclusion Disease
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that all randomized pediatric MVID patients in Napo's pivotal crossover clinical trial have entered the
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
